Compare Moderna, Inc. (MRNA) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Moderna, Inc. trades at $137.4 (market cap $56.02B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.65. The key difference: Moderna, Inc. is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | QDTE | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $174.38 | $36.60 |
52-Week Low | $22.36 | $26.85 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
QDTE trades at $28.86 with minimal daily movement (+0.07%). The ETF shows bearish technical signals with selling pressure outweighing buying signals 12-4. Recent news highlights concerns about the fund's sustainability as volatility declines and distributions are funded by return of capital, causing NAV erosion. The fund's 0.97% expense ratio consumes significant portions of its weekly payouts.
The outlook remains cautious given structural concerns about the fund's distribution model. While weekly income appeals to investors, the erosion of net asset value and dependence on return of capital present significant risks. Analyst sentiment has turned negative with recent downgrades citing underperformance in bull markets and unsustainable yield mechanics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
